1[1]Schafer SG, Christen MO, Ernsberger PR. The second generation of centrally acting drugs: Moxonidine. J Cardiovasc Pharmacol, 1992;20(Suppl.4):Ⅶ～Ⅷ
2[2]Szabo B, Urban R, Limberger N, Starke K. Cardiovascular effects of agmatine a"clonidine-displacing substance”, in conscious rabbits. Naunyn Schmiedebergs Arch Pharmacol, 1995;351(3):268～73
3[3]Saelens JK, Granat FR, Sawyer WK. The mouse jumping test:A simple screening method to estimate the physical dependence capacity of analgesics. Arch Int Pharmacodyn Ther, 1971;190(2):213～8
4[4]Ramaswamy S, Pillai NP, Gopalakrishnan V et al. Influence of clonidine on acute tolerance pattern to morphine induced anaglesia and sensitivity changes in mice. Life Sci, 1981;28(20):2237～41
5[5]Spaulding TC, Fielding S, Venafro JJ, Lal H. Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur J Pharmacol, 1979;58(1):19～25
